市場調査レポート

商品コード

1725148

ウロキナーゼ市場の2032年までの予測：タイプ、供給源、投与経路、用途、エンドユーザー、地域別の世界分析

Urokinase Market Forecasts to 2032 - Global Analysis By Type (Urokinase Powder and Urokinase Solution), Source, Route of Administration, Application, End User and By Geography

出版日: 2025年05月03日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,150 601,210円

レポートPDFを1名様のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回のみ可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (2-5 User License)

USD 5,250 760,567円

レポートPDFを同一事業所（所在地）内の5名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF & Excel (Site License)

USD 6,350 919,924円

レポートPDFおよびExcelを同一事業所（所在地）内のすべての方にご利用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は5回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Global Site License)

USD 7,500 1,086,525円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等のコピーは可能です。PDFおよびExcelの印刷は10回まで可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=144.87円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Stratistics MRCによると、ウロキナーゼの世界市場は2025年に20億8,000万米ドルを占め、予測期間中のCAGRは7.7%で、2032年には35億米ドルに達する見込みです。

ウロキナーゼは血栓溶解酵素であり、体内の血栓を溶解するために医療用に使用されます。もともとはヒトの尿に由来するセリン・プロテアーゼであるが、現在では組換えDNA技術を用いて生産されるのが一般的です。ウロキナーゼはプラスミノーゲンをプラスミンに変換し、血栓の主要蛋白成分であるフィブリンを分解する酵素として働きます。主に肺塞栓症、深部静脈血栓症、カテーテル閉塞などの治療に使用されます。ウロキナーゼは線溶薬として、閉塞した血管の血流回復に重要な役割を果たし、救急医療やインターベンショナル医療における重要な治療選択肢となっています。

英国心臓財団（British Heart Foundation）の2024年の記事によると、英国では760万人が心臓および循環器系疾患で生活しています。

血栓性疾患の有病率の上昇

血栓性疾患の罹患率の増加は、血栓溶解治療のニーズの高まりによりウロキナーゼ市場を促進しています。酵素ウロキナーゼは血栓を分解するために使用され、肺塞栓症、深部静脈血栓症、急性心筋梗塞などの治療において重要な役割を果たしています。これらの疾患の世界の有病率が、特に高齢化した人々の間で上昇するにつれて、効果的な血栓溶解治療に対する需要が増加しています。この動向はウロキナーゼ市場に利益をもたらし、その生産と応用のさらなる開拓に拍車をかけています。

高い治療費

高額な治療費は、特に中低所得地域における患者やヘルスケアプロバイダーのアクセスを制限することにより、ウロキナーゼ市場の成長を著しく阻害しています。このような高額な治療費は、ウロキナーゼをベースとする治療法の普及を抑制し、より安価な代替療法が求められるようになります。さらに、高額な費用はヘルスケア予算を圧迫し、保険適用を阻害し、広範な臨床使用を制限するため、最終的に市場の拡大を遅らせ、血栓溶解療法の技術革新を阻害します。

ドラッグデリバリーの技術的進歩

ドラッグデリバリーシステムの技術進歩は、その治療効果と精度を高めることにより、ウロキナーゼ市場に大きな影響を与えています。標的送達メカニズムやナノ粒子ベースの製剤などの技術革新は、より優れたバイオアベイラビリティと副作用の軽減を保証します。これらの進歩により、特定の部位を標的とする薬剤の能力が向上し、血栓や心臓発作などの疾患の治療が最適化されます。さらに、放出制御技術と個別化ドラッグデリバリーシステムは患者の転帰改善に寄与し、ウロキナーゼ市場の需要と成長を促進します。

出血合併症のリスク

出血性合併症のリスクはウロキナーゼ市場の成長を著しく阻害します。血栓溶解剤であるウロキナーゼは、特に基礎疾患を有する患者や抗凝固剤を投与中の患者において内出血を引き起こす可能性が高いです。この安全性の懸念により、ヘルスケア提供者の間でのウロキナーゼの普及には限界があり、慎重な処方が求められています。さらに、規制上の制限や、より安全な代替薬の利用可能性が市場の拡大をさらに抑制し、需要と市場全体のパフォーマンスにマイナスの影響を与えています。

COVID-19の影響

COVID-19の大流行により、ウロキナーゼ市場は、待機的手術の遅延、入院の減少、サプライチェーンの中断などの影響を受け、大きく混乱しました。パンデミックのピーク時には、ウロキナーゼのような血栓溶解剤を含むCOVID関連以外の治療薬に対する需要が減少しました。しかし、ヘルスケアシステムが安定し、外科手術が再開されると、市場は回復し始めました。さらに、COVID-19患者の血栓性合併症に対する意識の高まりが、抗凝固療法や血栓溶解療法の需要を間接的に支えました。

予測期間中、ウロキナーゼ溶液セグメントが最大となる見込み

ウロキナーゼ溶液セグメントは、予測期間中に最大の市場シェアを占めると予想されます。ウロキナーゼ溶液、特に静脈内投与および局所投与の形態は、血栓を迅速に溶解する能力により好まれるようになっており、肺塞栓症や深部静脈血栓症のような状態における患者の転帰を改善します。病院やヘルスケア施設におけるウロキナーゼ製剤の採用が拡大していることに加え、現在も研究が進められていることも、同分野の市場拡大にプラスの影響を与えています。

深部静脈血栓症セグメントは予測期間中に最も高いCAGRが見込まれる

予測期間中、深部静脈血栓症分野は、血栓性疾患の罹患率の上昇と早期診断・治療に対する意識の高まりにより、最も高い成長率を示すと予測されます。血栓溶解剤であるウロキナーゼは、DVT患者の血栓溶解に広く使用されており、その需要が拡大しています。ヘルスケアインフラの進歩や高齢化も市場拡大に寄与しています。この動向は、DVTをウロキナーゼ市場の持続的成長と技術革新を促進する重要な要因として位置付けています。

最大のシェアを占める地域

予測期間中、アジア太平洋が最大の市場シェアを占めると予想されます。これは、心血管疾患の増加、認知度の向上、先進治療へのアクセス改善が需要を牽引しているためです。この成長は技術革新を促進し、投資を促し、発展途上国全体で患者の転帰を改善しています。さらに、政府の支援とヘルスケアインフラの拡大が市場浸透を加速させ、救命のための血栓溶解療法をより身近なものとし、最終的には公衆衛生の向上と地域の医薬品状況の強化に寄与しています。

CAGRが最も高い地域：

予測期間中、北米地域は血栓溶解療法の認知度向上により、最も高いCAGRを示すと予測されます。ヘルスケアインフラの進歩、主要製薬企業の存在感、支持的な規制の枠組みが市場拡大をさらに後押しします。高齢者人口の増加と低侵襲治療への需要は、ウロキナーゼをベースとした治療の普及を促進します。これらの要因が相まって、患者の予後が大幅に改善され、地域市場の成長と革新が促進されています。

無料のカスタマイズサービス

本レポートをご購読のお客様は、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

企業プロファイル
- 追加市場企業の包括的プロファイリング（3社まで）
- 主要企業のSWOT分析（3社まで）
地域セグメンテーション
- 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
競合ベンチマーキング
- 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- 英国
- イタリア
- フランス
- スペイン
- その他の欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- ニュージーランド
- 韓国
- その他のアジア太平洋
南米
- アルゼンチン
- ブラジル
- チリ
- その他の南米
中東・アフリカ
- サウジアラビア
- アラブ首長国連邦
- カタール
- 南アフリカ
- その他の中東・アフリカ

第11章主な発展

契約、パートナーシップ、コラボレーション、ジョイントベンチャー
買収と合併
新製品発売
事業拡大
その他の主要戦略

第12章企業プロファイリング

Syner-Med Ltd.
Microbix Biosystems Inc.
Wuxi Green Pharmaceutical Co., Ltd.
Jiangxi Haoran Bio-Pharma Co., Ltd.
Medicure Inc.
Lee's Pharmaceutical Holdings Ltd.
Taj Pharmaceuticals Limited
Jiangsu Techpool Bio-Pharma Co., Ltd.
Guangzhou Recomgen Biotech Co., Ltd.
LGM Pharma
ScienCell Research Laboratories, Inc.
BioVision, Inc.
Abbott Laboratories
Enzo Life Sciences, Inc.
Molecular Innovations, Inc.
Prospec-Tany Technogene Ltd.
Wuhan YZY Biopharma Co., Ltd.
GenScript Biotech Corporation
Chymotech AS

図表

List of Tables

Table 1 Global Urokinase Market Outlook, By Region (2024-2032) ($MN)
Table 2 Global Urokinase Market Outlook, By Type (2024-2032) ($MN)
Table 3 Global Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
Table 4 Global Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
Table 5 Global Urokinase Market Outlook, By Source (2024-2032) ($MN)
Table 6 Global Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
Table 7 Global Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
Table 8 Global Urokinase Market Outlook, By Administration (2024-2032) ($MN)
Table 9 Global Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
Table 10 Global Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
Table 11 Global Urokinase Market Outlook, By Application (2024-2032) ($MN)
Table 12 Global Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
Table 13 Global Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
Table 14 Global Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
Table 15 Global Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
Table 16 Global Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
Table 17 Global Urokinase Market Outlook, By End User (2024-2032) ($MN)
Table 18 Global Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
Table 19 Global Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
Table 20 Global Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
Table 21 Global Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
Table 22 North America Urokinase Market Outlook, By Country (2024-2032) ($MN)
Table 23 North America Urokinase Market Outlook, By Type (2024-2032) ($MN)
Table 24 North America Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
Table 25 North America Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
Table 26 North America Urokinase Market Outlook, By Source (2024-2032) ($MN)
Table 27 North America Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
Table 28 North America Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
Table 29 North America Urokinase Market Outlook, By Administration (2024-2032) ($MN)
Table 30 North America Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
Table 31 North America Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
Table 32 North America Urokinase Market Outlook, By Application (2024-2032) ($MN)
Table 33 North America Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
Table 34 North America Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
Table 35 North America Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
Table 36 North America Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
Table 37 North America Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
Table 38 North America Urokinase Market Outlook, By End User (2024-2032) ($MN)
Table 39 North America Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
Table 40 North America Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
Table 41 North America Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
Table 42 North America Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
Table 43 Europe Urokinase Market Outlook, By Country (2024-2032) ($MN)
Table 44 Europe Urokinase Market Outlook, By Type (2024-2032) ($MN)
Table 45 Europe Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
Table 46 Europe Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
Table 47 Europe Urokinase Market Outlook, By Source (2024-2032) ($MN)
Table 48 Europe Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
Table 49 Europe Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
Table 50 Europe Urokinase Market Outlook, By Administration (2024-2032) ($MN)
Table 51 Europe Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
Table 52 Europe Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
Table 53 Europe Urokinase Market Outlook, By Application (2024-2032) ($MN)
Table 54 Europe Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
Table 55 Europe Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
Table 56 Europe Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
Table 57 Europe Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
Table 58 Europe Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
Table 59 Europe Urokinase Market Outlook, By End User (2024-2032) ($MN)
Table 60 Europe Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
Table 61 Europe Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
Table 62 Europe Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
Table 63 Europe Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
Table 64 Asia Pacific Urokinase Market Outlook, By Country (2024-2032) ($MN)
Table 65 Asia Pacific Urokinase Market Outlook, By Type (2024-2032) ($MN)
Table 66 Asia Pacific Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
Table 67 Asia Pacific Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
Table 68 Asia Pacific Urokinase Market Outlook, By Source (2024-2032) ($MN)
Table 69 Asia Pacific Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
Table 70 Asia Pacific Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
Table 71 Asia Pacific Urokinase Market Outlook, By Administration (2024-2032) ($MN)
Table 72 Asia Pacific Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
Table 73 Asia Pacific Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
Table 74 Asia Pacific Urokinase Market Outlook, By Application (2024-2032) ($MN)
Table 75 Asia Pacific Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
Table 76 Asia Pacific Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
Table 77 Asia Pacific Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
Table 78 Asia Pacific Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
Table 79 Asia Pacific Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
Table 80 Asia Pacific Urokinase Market Outlook, By End User (2024-2032) ($MN)
Table 81 Asia Pacific Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
Table 82 Asia Pacific Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
Table 83 Asia Pacific Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
Table 84 Asia Pacific Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
Table 85 South America Urokinase Market Outlook, By Country (2024-2032) ($MN)
Table 86 South America Urokinase Market Outlook, By Type (2024-2032) ($MN)
Table 87 South America Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
Table 88 South America Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
Table 89 South America Urokinase Market Outlook, By Source (2024-2032) ($MN)
Table 90 South America Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
Table 91 South America Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
Table 92 South America Urokinase Market Outlook, By Administration (2024-2032) ($MN)
Table 93 South America Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
Table 94 South America Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
Table 95 South America Urokinase Market Outlook, By Application (2024-2032) ($MN)
Table 96 South America Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
Table 97 South America Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
Table 98 South America Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
Table 99 South America Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
Table 100 South America Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
Table 101 South America Urokinase Market Outlook, By End User (2024-2032) ($MN)
Table 102 South America Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
Table 103 South America Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
Table 104 South America Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
Table 105 South America Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)
Table 106 Middle East & Africa Urokinase Market Outlook, By Country (2024-2032) ($MN)
Table 107 Middle East & Africa Urokinase Market Outlook, By Type (2024-2032) ($MN)
Table 108 Middle East & Africa Urokinase Market Outlook, By Urokinase Powder (2024-2032) ($MN)
Table 109 Middle East & Africa Urokinase Market Outlook, By Urokinase Solution (2024-2032) ($MN)
Table 110 Middle East & Africa Urokinase Market Outlook, By Source (2024-2032) ($MN)
Table 111 Middle East & Africa Urokinase Market Outlook, By Human-derived Urokinase (2024-2032) ($MN)
Table 112 Middle East & Africa Urokinase Market Outlook, By Recombinant Urokinase (2024-2032) ($MN)
Table 113 Middle East & Africa Urokinase Market Outlook, By Administration (2024-2032) ($MN)
Table 114 Middle East & Africa Urokinase Market Outlook, By Intravenous (2024-2032) ($MN)
Table 115 Middle East & Africa Urokinase Market Outlook, By Intracatheter (2024-2032) ($MN)
Table 116 Middle East & Africa Urokinase Market Outlook, By Application (2024-2032) ($MN)
Table 117 Middle East & Africa Urokinase Market Outlook, By Pulmonary Embolism (2024-2032) ($MN)
Table 118 Middle East & Africa Urokinase Market Outlook, By Deep Vein Thrombosis (2024-2032) ($MN)
Table 119 Middle East & Africa Urokinase Market Outlook, By Catheter Occlusion (2024-2032) ($MN)
Table 120 Middle East & Africa Urokinase Market Outlook, By Myocardial Infarction (2024-2032) ($MN)
Table 121 Middle East & Africa Urokinase Market Outlook, By Other Application (2024-2032) ($MN)
Table 122 Middle East & Africa Urokinase Market Outlook, By End User (2024-2032) ($MN)
Table 123 Middle East & Africa Urokinase Market Outlook, By Hospitals (2024-2032) ($MN)
Table 124 Middle East & Africa Urokinase Market Outlook, By Specialty Clinics (2024-2032) ($MN)
Table 125 Middle East & Africa Urokinase Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
Table 126 Middle East & Africa Urokinase Market Outlook, By Other End Users (2024-2032) ($MN)

Product Code: SMRC29294

According to Stratistics MRC, the Global Urokinase Market is accounted for $2.08 billion in 2025 and is expected to reach $3.50 billion by 2032 growing at a CAGR of 7.7% during the forecast period. Urokinase is a thrombolytic enzyme used medically to dissolve blood clots in the body. It is a serine protease originally derived from human urine, but now commonly produced using recombinant DNA technology. Urokinase works by converting plasminogen to plasmin, an enzyme that breaks down fibrin, the primary protein component of blood clots. It is primarily used to treat conditions such as pulmonary embolism, deep vein thrombosis, and catheter blockages. As a fibrinolytic agent, urokinase plays a vital role in restoring blood flow in occluded vessels, making it a critical therapeutic option in emergency and interventional medicine.

According to 2024 article by British Heart Foundation, 7.6 million people are living in with heart and circulatory disease in UK.

Market Dynamics:

Driver:

Rising Prevalence of Thrombotic Disorders

The growing incidence of thrombotic disorders is propelling the urokinase market due to the heightened need for thrombolytic treatments. The enzyme urokinase, which is employed to break down blood clots, plays a vital role in the treatment of conditions like pulmonary embolism, deep vein thrombosis, and acute myocardial infarction. As the global prevalence of these disorders rises, particularly among aging populations, the demand for effective clot-dissolving treatments is increasing. This trend is benefiting the urokinase market and spurring further developments in its production and application.

Restraint:

High Treatment Costs

High treatment costs significantly hinder the growth of the urokinase market by limiting accessibility for patients and healthcare providers, particularly in low- and middle-income regions. These elevated expenses reduce the adoption of urokinase-based therapies, as more affordable alternatives are sought. Additionally, high costs strain healthcare budgets, discourage insurance coverage, and restrict widespread clinical use, ultimately slowing market expansion and impeding innovation in thrombolytic treatments.

Opportunity:

Technological Advancements in Drug Delivery

Technological advancements in drug delivery systems have significantly impacted the Urokinase market by enhancing its therapeutic efficacy and precision. Innovations such as targeted delivery mechanisms and nanoparticle-based formulations ensure better bioavailability and reduced side effects. These advancements improve the drug's ability to target specific sites, optimizing the treatment of conditions like blood clots and heart attacks. Additionally, controlled release technologies and personalized drug delivery systems contribute to improved patient outcomes, driving demand and growth within the Urokinase market.

Threat:

Risk of Bleeding Complications

The risk of bleeding complications significantly hinders the growth of the urokinase market. Urokinase, a thrombolytic agent, carries a high potential for causing internal bleeding, particularly in patients with underlying conditions or on anticoagulants. This safety concern limits its widespread adoption among healthcare providers, prompting cautious prescription practices. Additionally, regulatory restrictions and the availability of safer alternatives further restrain market expansion, negatively impacting demand and overall market performance.

Covid-19 Impact

The COVID-19 pandemic significantly disrupted the urokinase market due to delays in elective surgeries, reduced hospital admissions, and supply chain interruptions. Demand for non-COVID-related therapies, including thrombolytic agents like urokinase, declined during the peak of the pandemic. However, as healthcare systems stabilized and surgical procedures resumed, the market began recovering. Additionally, increased awareness of thrombotic complications in COVID-19 patients indirectly supported demand for anticoagulant and thrombolytic therapies.

The urokinase solution segment is expected to be the largest during the forecast period

The urokinase solution segment is expected to account for the largest market share during the forecast period because Urokinase solutions, particularly in intravenous and local delivery forms, are gaining preference due to their ability to rapidly dissolve blood clots, improving patient outcomes in conditions like pulmonary embolism and deep vein thrombosis. The growing adoption of urokinase solutions in hospitals and healthcare facilities, combined with ongoing research, is further fueling the segment's positive impact on market expansion.

The deep vein thrombosis segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the deep vein thrombosis segment is predicted to witness the highest growth rate, due to the rising incidence of thrombotic disorders and increased awareness of early diagnosis and treatment. Urokinase, a thrombolytic agent, is widely used to dissolve blood clots in DVT patients, leading to its growing demand. Advancements in healthcare infrastructure and an aging population further contribute to market expansion. This trend positions DVT as a key driver fueling sustained growth and innovation in the urokinase market.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share due to rising cardiovascular cases, increased awareness, and improved access to advanced therapies are driving demand. This growth is fostering innovation, encouraging investments, and improving patient outcomes across developing nations. Additionally, government support and expanding healthcare infrastructure are accelerating market penetration, making life-saving thrombolytic therapies more accessible, ultimately contributing to better public health and a stronger regional pharmaceutical landscape.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to increasing awareness of thrombolytic therapies. Advancements in healthcare infrastructure, strong presence of key pharmaceutical players, and supportive regulatory frameworks further fuel market expansion. The growing geriatric population and demand for minimally invasive procedures enhance the uptake of urokinase-based treatments. Collectively, these factors are significantly improving patient outcomes and driving the regional market's growth and innovation.

Key players in the market

Some of the key players profiled in the Urokinase Market include Syner-Med Ltd., Microbix Biosystems Inc., Wuxi Green Pharmaceutical Co., Ltd., Jiangxi Haoran Bio-Pharma Co., Ltd., Medicure Inc., Lee's Pharmaceutical Holdings Ltd., Taj Pharmaceuticals Limited, Jiangsu Techpool Bio-Pharma Co., Ltd., Guangzhou Recomgen Biotech Co., Ltd., LGM Pharma, ScienCell Research Laboratories, Inc., BioVision, Inc., Abbott Laboratories, Enzo Life Sciences, Inc., Molecular Innovations, Inc., Prospec-Tany Technogene Ltd., Wuhan YZY Biopharma Co., Ltd., GenScript Biotech Corporation and Chymotech AS.

Key Developments:

In August 2024, Abbott and Medtronic announced a significant global partnership, to integrate Abbott's FreeStyle Libre continuous glucose monitoring (CGM) technology with Medtronic's insulin delivery systems. This collaboration aims to enhance diabetes management by enabling automatic insulin adjustments based on real-time glucose data.

In June 2024, Abbott has partnered with the National Association of Community Health Centers (NACHC) to improve access to nutritious food and health services. The collaboration aims to enhance healthcare delivery and address the growing health challenges related to nutrition in underserved communities.

Types Covered:

Urokinase Powder
Urokinase Solution

Sources Covered:

Human-derived Urokinase
Recombinant Urokinase

Routes of Administration Covered:

Intravenous
Intracatheter

Applications Covered:

Pulmonary Embolism
Deep Vein Thrombosis
Catheter Occlusion
Myocardial Infarction
Other Application

End Users Covered:

Hospitals
Specialty Clinics
Ambulatory Surgical Centers
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Urokinase Market, By Type

5.1 Introduction
5.2 Urokinase Powder
5.3 Urokinase Solution

6 Global Urokinase Market, By Source

6.1 Introduction
6.2 Human-derived Urokinase
6.3 Recombinant Urokinase

7 Global Urokinase Market, By Route of Administration

7.1 Introduction
7.2 Intravenous
7.3 Intracatheter

8 Global Urokinase Market, By Application

8.1 Introduction
8.2 Pulmonary Embolism
8.3 Deep Vein Thrombosis
8.4 Catheter Occlusion
8.5 Myocardial Infarction
8.6 Other Application

9 Global Urokinase Market, By End User

9.1 Introduction
9.2 Hospitals
9.3 Specialty Clinics
9.4 Ambulatory Surgical Centers
9.5 Other End Users

10 Global Urokinase Market, By Geography

10.1 Introduction
10.2 North America
- 10.2.1 US
- 10.2.2 Canada
- 10.2.3 Mexico
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 Italy
- 10.3.4 France
- 10.3.5 Spain
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 New Zealand
- 10.4.6 South Korea
- 10.4.7 Rest of Asia Pacific
10.5 South America
- 10.5.1 Argentina
- 10.5.2 Brazil
- 10.5.3 Chile
- 10.5.4 Rest of South America
10.6 Middle East & Africa
- 10.6.1 Saudi Arabia
- 10.6.2 UAE
- 10.6.3 Qatar
- 10.6.4 South Africa
- 10.6.5 Rest of Middle East & Africa

11 Key Developments

11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies

12 Company Profiling

12.1 Syner-Med Ltd.
12.2 Microbix Biosystems Inc.
12.3 Wuxi Green Pharmaceutical Co., Ltd.
12.4 Jiangxi Haoran Bio-Pharma Co., Ltd.
12.5 Medicure Inc.
12.6 Lee's Pharmaceutical Holdings Ltd.
12.7 Taj Pharmaceuticals Limited
12.8 Jiangsu Techpool Bio-Pharma Co., Ltd.
12.9 Guangzhou Recomgen Biotech Co., Ltd.
12.10 LGM Pharma
12.11 ScienCell Research Laboratories, Inc.
12.12 BioVision, Inc.
12.13 Abbott Laboratories
12.14 Enzo Life Sciences, Inc.
12.15 Molecular Innovations, Inc.
12.16 Prospec-Tany Technogene Ltd.
12.17 Wuhan YZY Biopharma Co., Ltd.
12.18 GenScript Biotech Corporation
12.19 Chymotech AS

ウロキナーゼ市場の2032年までの予測：タイプ、供給源、投与経路、用途、エンドユーザー、地域別の世界分析

Urokinase Market Forecasts to 2032 - Global Analysis By Type (Urokinase Powder and Urokinase Solution), Source, Route of Administration, Application, End User and By Geography

最大のシェアを占める地域

CAGRが最も高い地域：

無料のカスタマイズサービス

本レポートをご購読のお客様は、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

第4章 ポーターのファイブフォース分析

第5章 世界のウロキナーゼ市場：タイプ別

第6章 世界のウロキナーゼ市場：供給源別

第7章 世界のウロキナーゼ市場：投与経路別

第8章 世界のウロキナーゼ市場：用途別

第9章 世界のウロキナーゼ市場：エンドユーザー別

第10章 世界のウロキナーゼ市場：地域別

第11章 主な発展

第12章 企業プロファイリング